CN116507622B - Gpr52调节剂化合物 - Google Patents

Gpr52调节剂化合物

Info

Publication number
CN116507622B
CN116507622B CN202180073276.0A CN202180073276A CN116507622B CN 116507622 B CN116507622 B CN 116507622B CN 202180073276 A CN202180073276 A CN 202180073276A CN 116507622 B CN116507622 B CN 116507622B
Authority
CN
China
Prior art keywords
disorder
tetrahydro
pyridin
compound
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180073276.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN116507622A (zh
Inventor
萨拉·乔安妮·巴克内尔
斯蒂芬·保罗·沃森
迈克尔·阿里斯泰尔·奥布莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hepares Treatment Co ltd
Nexla Pharmaceuticals Uk Ltd
Original Assignee
Hepares Treatment Co ltd
Nexla Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hepares Treatment Co ltd, Nexla Pharmaceuticals Uk Ltd filed Critical Hepares Treatment Co ltd
Publication of CN116507622A publication Critical patent/CN116507622A/zh
Application granted granted Critical
Publication of CN116507622B publication Critical patent/CN116507622B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Amplifiers (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180073276.0A 2020-08-28 2021-08-31 Gpr52调节剂化合物 Active CN116507622B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2013558.8 2020-08-28
GBGB2013558.8A GB202013558D0 (en) 2020-08-28 2020-08-28 GRP52 Modularor compounds
PCT/GB2021/052247 WO2022043714A1 (en) 2020-08-28 2021-08-31 Gpr52 modulator compounds

Publications (2)

Publication Number Publication Date
CN116507622A CN116507622A (zh) 2023-07-28
CN116507622B true CN116507622B (zh) 2026-02-24

Family

ID=72749711

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180073276.0A Active CN116507622B (zh) 2020-08-28 2021-08-31 Gpr52调节剂化合物

Country Status (12)

Country Link
US (1) US20230348416A1 (enExample)
EP (1) EP4204408A1 (enExample)
JP (1) JP7761635B6 (enExample)
KR (1) KR20230058132A (enExample)
CN (1) CN116507622B (enExample)
AU (1) AU2021330379A1 (enExample)
BR (1) BR112023003696A2 (enExample)
CA (1) CA3193487A1 (enExample)
GB (1) GB202013558D0 (enExample)
IL (1) IL301007B2 (enExample)
MX (1) MX2023002389A (enExample)
WO (1) WO2022043714A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
CN122555695A (zh) * 2023-11-29 2026-08-11 爱克堤欧生物科学股份有限公司 可用作kcnt1抑制剂的杂环化合物
CN121313618B (zh) * 2025-12-09 2026-07-21 杭州师范大学附属医院(杭州市第二人民医院) 丙酸在制备治疗肝豆状核变性肠肝轴紊乱的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108174603A (zh) * 2015-04-29 2018-06-15 阿芮纳制药有限公司 作为gpr52调节剂的用于治疗或预防其相关病症的1-杂芳基-二氢吲哚-4-甲酰胺
CN108349947A (zh) * 2015-11-02 2018-07-31 S·莱恩 四氢吲唑及其医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021009003A1 (en) * 2019-07-16 2021-01-21 Universität Hamburg Computer-based identification of types in the empirical sciences by tangle theory
CN114650992A (zh) * 2019-11-08 2022-06-21 赫普泰雅治疗有限公司 Gpr52调节剂化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108174603A (zh) * 2015-04-29 2018-06-15 阿芮纳制药有限公司 作为gpr52调节剂的用于治疗或预防其相关病症的1-杂芳基-二氢吲哚-4-甲酰胺
CN108349947A (zh) * 2015-11-02 2018-07-31 S·莱恩 四氢吲唑及其医药用途

Also Published As

Publication number Publication date
IL301007B1 (en) 2026-04-01
IL301007A (en) 2023-05-01
WO2022043714A1 (en) 2022-03-03
US20230348416A1 (en) 2023-11-02
MX2023002389A (es) 2023-05-03
BR112023003696A2 (pt) 2023-04-04
KR20230058132A (ko) 2023-05-02
EP4204408A1 (en) 2023-07-05
AU2021330379A1 (en) 2023-03-30
CN116507622A (zh) 2023-07-28
CA3193487A1 (en) 2022-03-03
IL301007B2 (en) 2026-08-01
JP2023539336A (ja) 2023-09-13
JP7761635B2 (ja) 2025-10-28
JP7761635B6 (ja) 2025-11-27
GB202013558D0 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
JP7761635B2 (ja) Ｇｐｒ５２モジュレーター化合物
CN103298809B (zh) 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN115515681B (zh) Gpr52调节剂化合物
CA3203285A1 (en) Heteroaryl carboxamide compound
US20100292266A1 (en) Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase
CA3047404A1 (en) Compounds, compositions and methods of use
WO2013131018A1 (en) Biaryl inhibitors of the sodium channel
CN115210233B (zh) 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物
KR20200014915A (ko) 디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도
CN117440955A (zh) 具有食欲素-2受体激动剂活性的取代的酰胺大环化合物
US20240408064A1 (en) Ras inhibitors, compositions and methods of use thereof
JP5635181B2 (ja) ニトロイミダゾール系化合物、その製造方法および用途
WO2016121782A1 (ja) スルホンアミド化合物
TWI924820B (zh) 1,3-取代的環丁基衍生物及其用途
EP4401833B1 (en) Gpr52 modulator compounds
CN115515943A (zh) 噁二唑衍生物
EP2524912A1 (en) Amine derivatives
EP3980401B1 (en) Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders
RS61886B1 (sr) Fluoropiperidinska jedinjenja kao čisti antagonisti 5-ht6 receptora
HK40107480B (en) Gpr52 modulator compounds
HK40107480A (en) Gpr52 modulator compounds
CN115784986A (zh) 一种hdac6抑制剂及其制备方法和应用
KR20220098160A (ko) 아드레날린수용체 adrac2의 억제제
EA040294B1 (ru) Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht6-рецептора
HK40023760B (en) Sulfonamide compounds and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Britain

Address after: Britain

Applicant after: Nexla Pharmaceuticals UK Ltd.

Address before: Cambridge County, England

Applicant before: Hepares Treatment Co.,Ltd.

Country or region before: Britain

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant